Drug
Fluzone Quadrivalent Vaccine
Fluzone Quadrivalent Vaccine: highest development phase Post-Market, developed by Sanofi. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation NCT04109222 | Post-Market | Influenza |
Latest
No recent events.
Follow Fluzone Quadrivalent Vaccine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.